# Qwen 3-Next 80B Thinking — deep_reasoning/ethical_dilemma_structured

- model_id: `qwen/qwen3-next-80b-a3b-thinking`
- success: True  | final: 7.18 | quality: 7.5
- latency_total: 13.74s | tokens_per_second: 149.1
- input_tokens: 205 | output_tokens: 2048
- judge_score: 4.0 | justificación: 

## Respuesta completa

Okay, let's tackle this problem step by step. So, the startup has an AI model for cancer detection with 95% precision, but there are some issues. The board wants a recommendation, and I need structured analysis. Let me start by identifying all stakeholders affected.

First, stakeholders... Hmm. Patients, obviously. Especially those with skin dark or light, since the model performs differently. Then healthcare providers—doctors, hospitals. They'd rely on this model. maybe insurance companies? They might be affected by unnecessary procedures. Also, the startup's employees, investors, maybe regulatory bodies like FDA. Oh, and the general public, because if the model is deployed with bias, it might affect public trust in AI. Also, people who are at risk of cancer but might not get detected if the model is not used. Wait, but the model has high precision, so maybe some people are getting false positives or false negatives, but the main issue here is the bias against dark skin.

Wait, precision is 95%, but they mention 5% false positives causing anxiety and unnecessary procedures. But then the model works worse in people with dark skin (90% vs 97% for light skin). So precision for dark skin is 90%, which is lower. But precision is true positives over (true positives + false positives). So lower precision in dark skin means more false positives relative to true positives. But the 5% false positives—maybe that's overall? Wait, the problem statement says " El 5% of falsos positivos causa ansiedad..." Wait, maybe they mean that 5% of the positive predictions are false positives? Because precision is 95%, which means 5% false positives. But then for dark skin, precision is 90% so 10% false positives. So higher false positive rate for dark skin. Which would lead to more unnecessary procedures and anxiety for that group. That makes sense.

So stakeholders: patients with dark skin (more false positives, more harm), patients with light skin (lower false positives, but still some), healthcare providers who might have to deal with more unnecessary procedures, maybe even the startup's reputation if the bias is known. Also, people who might not get diagnosed if the model is not used (false negatives). Wait, but precision is about positive predictions. To know about the false negatives, we need recall. But the problem doesn't mention recall. Hmm. The problem states "95% de precision"— so precision is 95%, but without knowing the recall, we don't know how many true cases are missed. But the problem says "lanzar ahora salvaria vidas"— so maybe the model's overall accuracy is high enough that even with some false positives and negatives, it's better than not using it. But the bias is a problem.

So stakeholders:

1. Cancer patients (divided into those with dark skin vs light skin): for dark skin, higher false positive rate (10% vs 5%), which leads to more unnecessary procedures and anxiety. But also, perhaps lower recall (if the 90% precision is due to lower true positives, but precision is not the same as recall). Wait, precision is about how many of the predicted positives are true positives. Recall is how many true positives are correctly identified. So if the model has lower precision for dark skin, that could mean more false positives, but maybe also lower recall? Not necessarily. It's possible that the recall is the same but precision is lower due to more false positives. But the problem doesn't specify. Maybe the 90% precision in dark skin is due to 90% of the positive predictions in that group are correct, while for light skin it's 97%. So for dark skin, 10% of positive predictions are false positives. For light skin, 3% false positives. But the problem says "5% of falsos positivos" overall. Wait, maybe the 95% precision overall, but split into 90% for dark and 97% for light. So the overall precision is 95% but with a subgroup difference.

But the exact numbers: "90% precision vs 97% en piel clara"—so for dark skin, precision is 90%, for light skin 97%. So the overall precision would depend on the proportion of each group in the population. Suppose 10% of the population has dark skin, 90% light. Then overall precision would be (0.1*90 + 0.9*97)/100 ≈ 96.3%. But the problem states the model has 95% precision overall. So maybe the split is different. But maybe the exact numbers aren't critical here; the point is that there's a disparity.

St stakeholders: as mentioned, patients ( dark vs light), healthcare providers, the startup's investors and employees, regulatory bodies, the public (trust in AI), maybe even the broader society if the bias perpetuates health disparities.

Now, moving on to trade-offs quantitatively. Let's try to model some numbers.

Assume a population of 100,000 people. Let's say 10% have dark skin (10,000), 90% light skin (90,000). Let's assume the prevalence of cancer in the population is, say, 1% (so 1,000 cases total). But maybe we need to know the actual prevalence for each group? Suppose in dark skin, prevalence is higher or same? For simplicity, maybe assume same prevalence across both groups, 1%.

So in dark skin group: 10,000 people, 100 cancer cases, 9,900 healthy.

Precision for dark skin is 90%. So of all positive predictions, 90% are true. But to compute false positives, need to know how many positives are predicted. Let's say TP (true positives) + FP (False positives) = total predicted positives. Precision = TP / ( TP + FP ) = 0.9. So TP = 0.9*(TP+ FP), so 0.1 TP = 0.9 FP → FP = TP/9.

But also, recall (sensitivity) is TP / ( TP + FN ). But we don't know recall. The problem doesn't give recall data. Hmm. This complicates things. Alternatively, maybe the 95% precision is overall, but the false positive rate (FPR) is 5% overall. Wait, no: precision is different from FPR. FPR is FP / ( FP TN ), but precision is TP / ( TP + FP ). So they're different metrics.

But the problem states "5% of falsos positivos causa ans..." which probably refers to 5% false positive rate in the positive predictions (i.e., precision 95%). So for the model, 5% of the time when it says positive, it's wrong. But for dark skin, 10% of positive predictions are wrong (precision 90%), for light skin 3% (precision 97%).

But to compute the actual number of false positives, we need to know how many positive predictions are made. Let's make some assumptions.

Assume that the test is applied to 100,000 people. Suppose cancer prevalence is 1% (1,000 cases). Let's say the recall (sensitivity) is 80% for all groups (just an assumption, as the problem doesn't specify). So for the entire population:

True positives: 80% of 1,000 = 800.

False negatives: 200.

But precision is 95%, so TP / ( TP + FP ) = 0.95 → 800 / (800 + FP ) = 0.95 → 800 = 0.95*(800 + FP ) → 800 = 760 + 0.95 FP → 40 = 0.95 FP → FP � ≈ 42. So false positives are 42, total positive predictions 842. Then specificity would be TN / ( TN + FP ), but maybe not necessary.

But for dark skin vs light skin: let's say 10% of the population is dark skin (10,000 people), 90% light (90,000). Suppose cancer prevalence is same in both groups (1%), so 100 cases in dark, 900 in light.

Assume recall for dark skin is 80% (same as overall?), so TP dark = 80, FN dark = 20. Recall for light skin also 80%: TP light = 720, FN light = 180.

Precision for dark skin is 90%: TP / ( TP + FP ) = 0.9. So 80 / (80 + FP ) = 0.9 → 80 = 0.9*(80 + FP ) → 80 = 72 + 0.9 FP → 8 = 0.9 FP → FP ≈ 8.88, so ~9 FP in dark skin group.

Similarly, for light skin, precision 97%: TP = 720, so 720 / (720 + FP ) = 0.97 → 720 = 0.97*(720 + FP ) → 720 = 698.4 + 0.9 FP →